SION

Sionna Therapeutics Stock Analysis

AI Rating

Good
  • Quality5/10
  • Growth↓ 3/10
  • Value↑ 6/10
Sionna Therapeutics sales and earnings growth
SION Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 88.24%
  • FCF Y/Y↓ -26.24%
Sionna Therapeutics gross and profit margin trends
SION Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Sionna Therapeutics net debt vs free cash flow
SION Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Sionna Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗